Touyun Biotech Group Limited

SEHK:1332 Voorraadrapport

Marktkapitalisatie: HK$440.5m

Touyun Biotech Group Dividend

Dividend criteriumcontroles 0/6

Touyun Biotech Group heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

n/a

Uitbetalingsratio

Gemiddelde opbrengst industrie3.9%
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Winst per aandeel-HK$0.083
Dividendrendementsvoorspellingn/a

Recente dividendupdates

Geen updates

Recent updates

Revenues Not Telling The Story For Touyun Biotech Group Limited (HKG:1332) After Shares Rise 29%

Sep 15
Revenues Not Telling The Story For Touyun Biotech Group Limited (HKG:1332) After Shares Rise 29%

Touyun Biotech Group Limited's (HKG:1332) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jul 17
Touyun Biotech Group Limited's (HKG:1332) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Risks Still Elevated At These Prices As Touyun Biotech Group Limited (HKG:1332) Shares Dive 28%

Apr 22
Risks Still Elevated At These Prices As Touyun Biotech Group Limited (HKG:1332) Shares Dive 28%

Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?

Apr 08
Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?

What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You

Feb 07
What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You

Some Touyun Biotech Group Limited (HKG:1332) Shareholders Look For Exit As Shares Take 42% Pounding

Dec 18
Some Touyun Biotech Group Limited (HKG:1332) Shareholders Look For Exit As Shares Take 42% Pounding

Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt

Sep 19
Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Touyun Biotech Group Limited (HKG:1332)

Jul 28
Risks To Shareholder Returns Are Elevated At These Prices For Touyun Biotech Group Limited (HKG:1332)

Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

Sep 13
Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

Touyun Biotech Group (HKG:1332) Is Making Moderate Use Of Debt

May 18
Touyun Biotech Group (HKG:1332) Is Making Moderate Use Of Debt

Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

Dec 24
Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?

Mar 12
Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?

If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns

Jan 15
If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns

The Executive Chairman of China Touyun Tech Group Limited (HKG:1332), Liang Wang, Just Bought 8.8% More Shares

Jan 15
The Executive Chairman of China Touyun Tech Group Limited (HKG:1332), Liang Wang, Just Bought 8.8% More Shares

How Much Of China Touyun Tech Group Limited (HKG:1332) Do Insiders Own?

Dec 11
How Much Of China Touyun Tech Group Limited (HKG:1332) Do Insiders Own?

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van 1332 in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van 1332 zijn gestegen.


Dividendrendement versus markt

Touyun Biotech Group Dividendrendement versus markt
Hoe verhoudt 1332 dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (1332)n/a
Markt onderkant 25% (HK)3.2%
Markt Top 25% (HK)7.9%
Gemiddelde industrie (Packaging)3.9%
Analist prognose (1332) (tot 3 jaar)n/a

Opmerkelijk dividend: Het dividendrendement van 1332 kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van 1332 kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.


Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio 1332 te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat 1332 geen uitbetalingen heeft gerapporteerd.


Ontdek bedrijven met een sterk dividend